IRB, Office of Research Development COOK COUNTY BUREAU OF HEALTH SERVICES
Office of Research Development

      
Saturday, May 18, 2013
Home | Print this page | Email this page to a friend |
Developing Your Research
Rules & Regulations
Money
Taking Care?
 
  Institutional Links:
  CCH Intranet Links
  Cook County Bureau of   Health Services
  John Stroger Hospital
  Department of Medicine
  Educational Programs
  Email Access:
  CCHIL, RUSH & CCBHS
 

  IRB
  CCBHS
  627 S. Wood Street
  Chicago, IL 60612
  Phone: 312-864-0716
  Fax: 312-864-9210
 

MISCONDUCT IN SCIENCE
 
What is Scientific Misconduct?

Falsification

Fabrication

Plagiarism

Is Scientific Misconduct a Problem?

DHHS Policy Changes

New Federal-Wide Rule Proposed

New Definition of Scientific Misconduct

Working Definition of Plagiarism

New Bureau Policy

Bureau Research Integrity Officers

What is Scientific Misconduct?

Investigators are sometimes puzzled about what is covered by the term "scientific misconduct". Science is a system that depends on every participant maintaining high standards of conduct in a number of arenas. For instance, when living beings - whether human or animal – are the subjects of research, there are expectations about how they will be protected. When public funds support research, there are expectations about how they will be expended. When hazardous materials are used in research, there are expectations about how they will be handled to reduce any associated risks. In the arena of the scientific method itself, adherence to standards of truthfulness is necessary if the method is to produce valid knowledge. If scientific reports were filled with false data or misleading accounts of methods and procedures, the accumulated body of knowledge on which science is built would be shaky indeed. Not only would an investigator have no way to confidently move a research program forward, but real-life applications of scientific findings, especially clinical applications, would be unreliable, invalid, or even dangerous. "Scientific misconduct" refers specifically to violations of the expectation of honesty in reporting scientific findings. Violations of other expectations, such as those for protecting subjects mentioned earlier, are addressed by other policies and procedures.

Scientific misconduct has been defined as " fabrication, falsification, plagiarism, or other practices that significantly deviate from the commonly accepted practices of the scientific community with respect to the proposal, performance or reporting of research". As discussed later in this article, this definition has recently been revised to be more specific, but it is still based primarily on three ways in which one can be dishonest about carrying out and reporting research.

The following are examples of falsification, fabrication and plagiarism taken from a public notice of determinations made by the Office of Research Integrity (ORI)

Back to Top

Falsification

Raphael B. Stricker, M.D., University of California at San Francisco.
An investigation conducted by the University found that Dr. Stricker falsified data for a manuscript and a PHS-supported publication reporting research on AIDS. In the manuscript, Dr. Stricker selectively suppressed data that did not support his hypothesis, and reported consistently positive data whereas only one of four experiments had produced positive results. In the publication, Dr. Stricker reported that an antibody was found in 29 of 30 homosexuals, but not found in non-homosexuals. However, Dr. Stricker's control data, which he suppressed, showed the antibody in 33 of 65 non-homosexuals. The falsified data was used as the basis for a grant application to the National Institutes of Health. The ORI concurred in the University's finding. Dr. Stricker executed a Voluntary Exclusion and Settlement Agreement in which he has agreed not to apply for Federal grant or contract funds and will not serve on PHS advisory committees, boards or peer review groups for a three year period beginning April 1, 1993. The publication "Target platelet antigen in homosexual men with immune thrombocytopenia" in the New England Journal of Medicine, 313: 1315-1380, 1985 has been retracted (New England Journal of Medicine, 325: 1487,1991).

Back to Top

Fabrication and Falsification

Tian-Shing Lee, M.D., Joslin Diabetes Center, Harvard Medical School.
An investigation conducted by Harvard found that Dr. Lee, a former post-doctoral fellow at the Joslin Diabetes Center, fabricated and falsified data in research on diabetes supported by the National Eye Institute. Primary data was missing for almost half of the figures and tables in a series of published papers and manuscripts prepared by Dr. Lee. Many instances of data fabrication and falsification were found, including presenting data for cell counts that were never performed, indicating that multiple data points were determined when in fact only a single data point was obtained, eliminating the highest or lowest values in sets of experimental readings, alteration or transposition of data to achieve a desired experimental result, and misrepresentation of the time intervals at which data was collected. The Office of Research Integrity concurred in the University's findings. Dr. Lee has been debarred from receiving Federal grants or contracts and is prohibited from serving on Public Health Service Advisory Committees, Boards, or peer review groups for a five year period beginning April 18, 1993. Harvard University notified the four scientific journals which had published papers containing data fabricated or falsified by Dr. Lee that the papers should be retracted. These papers are: "Differential regulation of protein kinase C and (Na,K)-adenosine triphosphatase activities by elevated glucose level in retinal capillary endothelial cell" Journal of Clinical Investigation, 83: 90-94, 1989; "Endothelin stimulates a sustained 1,2-diacylglycerool increase and protein kinase C activation in bovine aortic smooth muscle cells" Biochemical and Biophysical Research Communications, 162: 381-386, 1989: "Activation of protein kinase C by elevation of glucose concentration: Proposal for a mechanism in the development of diabetic vascular complications" Proceedings of the National Academy of Sciences, 86: 5141-5145, 1989; and "Characterization of endothelin receptors and effects of endothelin on diacylglycerol and protein kinase C in retinal capillary pericytes" Diabetes, 38: 1642-1646, 1989.

Back to Top

Plagiarism

James H. Freisheim, Ph.D., Medical College of Ohio.
An inquiry and an investigation conducted by the University found that Dr. Freisheim had submitted a research grant application to the National Institutes of Health which contained substantial portions plagiarized from another scientist's grant application. Dr. Freisheim had served as an assigned reviewer of the other scientist's application when it was reviewed about two years earlier by an NIH Study Section. During the inquiry, Dr. Freisheim produced a handwritten draft of the plagiarized material that he claimed he had written before the other scientist had submitted his grant application, and that therefore the other scientist had plagiarized Dr. Freisheim's work. The investigation reviewed the handwritten draft and concluded that it had been written much later than purported by Dr. Freisheim, possibly during the inquiry to establish the basis for his defense. The investigation also concluded that Dr. Freisheim had plagiarized material for two post-doctoral fellowship applications to the NIH. The ORI concurred in the University's findings, and Dr. Freisheim has been debarred from receiving Federal grant or contract funds for a period of three years beginning May 5, 1993. He has also been required, for a ten year period beginning May 5, 1993, to certify that future applications for research support submitted to the PHS are his own work, and he has been prohibited from serving on PHS Advisory Committees or review groups for the same period.

Back to Top

Is Scientific Misconduct a Problem?

All persons who have been trained to carry out research understand that the scientific enterprise depends on a social compact of honesty in reporting. Many have questioned whether instances of fabrication, falsification or plagiarism are frequent enough to require a raft of bureaucratic rules and procedures. For the past three years, the number of new allegations of misconduct reported to federal regulators has been between 50 and 70 per year, with the numbers declining. Of these allegations, around 10-15% result in full investigations. Of the cases in which the federal Office of Research Integrity carries out an investigation, about 1/3 result in findings of misconduct. This translates to perhaps 9 or 10 cases of confirmed misconduct per year. In the vast world of scientific research, these are very small numbers.

However, it is impossible to know how many cases of misconduct go undiscovered. One thing both critics and supporters of the current system agree on: Ferreting out misconduct after it has happened is probably less effective and efficient than adequate training of researchers to avoid misconduct in the first place. For this reason, the ORI has decided to shift its focus to education, and the DHHS has adopted a rule requiring recipients of federal research funding to provide training in the responsible conduct of research to all staff engaged in research with PHS funds. This new requirement will apply to the entities of the Bureau.

Back to Top

DHHS Policy Changes, November, 1999

The Department of Health and Human Services operates a collaborative system for promoting integrity in biomedical and behavioral research supported or conducted by agencies of the U.S. Public Health Service (PHS). The system for preventing, detecting, and investigating scientific misconduct involves cooperative efforts among individual scientists, research institutions, and PHS agencies, especially the National Institutes of Health. The HHS Office of Research Integrity (ORI) monitors the system.

Institutions which carry out research funded by DHHS must make assurances that they have adopted appropriate policies and procedures for handling allegations of scientific misconduct. These assurances are made with each application for research funding, and are also supported by yearly reports made by the Research Integrity Officer.

In 1996, the HHS Secretary convened the Review Group on Research Misconduct and Research Integrity to examine the system under which the Department handles allegations of research misconduct, which included a review of the issues addressed by the Commission. In October 1999, the review group issued its recommendations, which were accepted by the Secretary. Under the proposals agreed to:

1. The Department will adopt through rulemaking a new definition of research misconduct that focuses on improper behaviors related specifically to the conduct of research. The definition, proposed by the National Science and Technology Council, will also be adopted by other federal agencies engaged in research [see box next section]

2. Institutions that administer PHS-supported grants will maintain responsibility for conducting initial inquiries and investigations when allegations of misconduct are made. However, when further fact finding is required by the federal government, it will be carried out by the Office of the Inspector General rather than the ORI, as previously was the case.

3. Inquiries and investigations into potential research misconduct will be separated from the decision making process of determining if misconduct occurred. The ORI will recommend findings and sanctions to the Assistant Secretary for Health, who will make the final decisions regarding misconduct, subject to appeal.

4. The Departmental Appeals Board (DAB) will continue to hear appeals from individuals who contest findings of misconduct. Each DAB appeals panel will include 2 scientists, and the appeals process will be streamlined with clarified procedures and rules for conducting hearings.

5. The Department will require research institutions to provide training in the responsible conduct of research to all staff engaged in research or research training with PHS funds. This expands an existing NIH requirement that applied only to research trainees.

Back to Top

New Federal-Wide Rule Proposed

The Federal Office of Science and Technology Policy has issued a proposed "Federal Policy on Research Misconduct To Protect the Integrity of the Research Record" with a request for public comment which will be open until December 13. This new rule will apply across all federal agencies. It adopts a definition of scientific misconduct that is consonant with the one recently adopted by HHS (see box) and also incorporates most of the procedural changes included in the new HHS policy.


New Definition of Scientific Misconduct
From the proposed "Federal Policy on Research Misconduct To Protect the Integrity of the Research Record"

Research misconduct is defined as fabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting research results.

1. Fabrication is making up results and recording or reporting them

2. Falsification is manipulating research materials, equipment, or processes, or changing or omitting data or results such that the research is not accurately represented in the research record.

The research record is defined as the record of data or results that embody the facts resulting from scientific inquiry, and includes, for example, laboratory records, both physical and electronic, research proposals, progress reports, abstracts, theses, oral presentations, internal reports, and journal articles.

3. Plagiarism is the appropriation of another person's ideas, processes, results, or words without giving appropriate credit, including those obtained through confidential review of others' research proposals and manuscripts.

Research misconduct does not include honest error or honest differences of opinion.

A finding of research misconduct requires that:


• There be a significant departure from accepted practices of the scientific community for maintaining the integrity of the research record;
• The misconduct be committed intentionally, or knowingly, or in reckless disregard of accepted practices; and
• The allegation be proven by a preponderance of evidence.
Other major points covered by the proposed policy are:
• Initial responsibility for investigation lies with the research institution;

• Multiple phases of the investigation are required, including inquiry, investigation and adjudication phases, with provisions for appeals;

• Separation of the phases, with adjudication decisions separated from the inquiry and investigation processes;

• Institutional notification of the agency, which specifies the circumstances in which the institution must notify the federal funding agency of a scientific misconduct investigation;

• Safeguards for informants;

• Safeguards for the subject of the allegation;

• Objectivity and expertise of individuals to review allegations and conduct investigations;

• Timeliness of the inquiry, investigation, adjudication, and appeal phases;

• Confidentiality during inquiry and investigation.

• Possible administrative actions for those found to have committed scientific misconduct

Back to Top

ORI PROVIDES WORKING DEFINITION OF PLAGIARISM

The following was prepared by the Office of Research Integrity to help researchers distinguish between plagiarism and other issues of contention, such as authorship disputes.

Although there is widespread agreement in the scientific community on including plagiarism as a major element of the PHS definition of scientific misconduct, there is some uncertainty about how the definition of plagiarism itself is applied in ORI cases.

As a general working definition, ORI considers plagiarism to include both the theft or misappropriation of intellectual property and the substantial unattributed textual copying of another's work. It does not include authorship or credit disputes.

The theft or misappropriation of intellectual property includes the unauthorized use of ideas or unique methods obtained by a privileged communication, such as a grant or manuscript review.

Substantial unattributed textual copying of another's work means the unattributed verbatim or nearly verbatim copying of sentences and paragraphs which materially mislead the ordinary reader regarding the contributions of the author. ORI generally does not pursue the limited use of identical or nearly-identical phrases which describe a commonly-used methodology or previous research because ORI does not consider such use as substantially misleading to the reader or of great significance.

Many allegations of plagiarism involve disputes among former collaborators who participated jointly in the development or conduct of a research project, but who subsequently went their separate ways and made independent use of the jointly developed concepts, methods, descriptive language, or other product of the joint effort. The ownership of the intellectual property in many such situations is seldom clear, and the collaborative history among the scientists often supports a presumption of implied consent to use the products of the collaboration by any of the former collaborators.

For this reason, ORI considers many such disputes to be authorship or credit disputes rather than plagiarism. Such disputes are referred to PHS agencies and extramural institutions for resolution.

Back to Top

New Bureau Policy

Under the new Bureau policy, responsibility for dealing with allegations of scientific misconduct is assigned to a Bureau Research Integrity Officer (RIO), assisted by an Associate Research Integrity Officer at each Bureau affiliate. Persons who have concerns about possible scientific misconduct may speak to one of these officers confidentially. When an allegation of misconduct is brought, the Associate RIO and the RIO will confer as to whether the alleged conduct falls within the definition of scientific misconduct and whether there is reasonably sufficient evidence to warrant further inquiry. If both conditions are met, a fact-finding inquiry will be carried out, by a small committee appointed by the RIO. The inquiry provides a preliminary review to separate serious allegations from frivolous, unjustified, or clearly mistaken conclusions which are drawn from observations.

If the inquiry committee finds that a full investigation is warranted, the Chief Operating Officer of the entity where the misconduct is alleged to have taken place will appoint a committee to investigate and report on the allegations. This report will be delivered to the Chief Operating Officer, who will decide if sanctions are called for.

The policy includes safeguards from retaliation for persons who bring complaints in good faith, and safeguards for persons accused of misconduct. The policy also delineates when the Bureau is obliged to report to ORI allegations that lead to inquiries or investigations. More....

Back to Top

Who Are the Bureau Research Integrity Officers?


The Bureau Research Integrity Officer is Dr. Robert Weinstein. He can be contacted at 312-633-3237

For Cook County Hospital, the Associate Research Integrity Officer is Keith Dookeran, MD, at 312-633-8207

For Provident Hospital, the Associate Research Integrity Officer is Clyniece Watson, MD, at 312-572-2684.

For Oak Forest Hospital, the Associate Research Integrity Officer is Henry Andoh, MD at 708-633-4193

For the Ambulatory & Community Health Network, the Associate Research Integrity Officer is Mildred Williamson at 312-747-7700.

For Cermak Health Services, the Associate Research Integrity Officer is Jean Kiriazes at 773-869-6575.

For the Cook County Department of Public Health, the Associate Research Integrity Officer is Steven M. Seweryn, at 708-492-2021.

Back to Top

See also:
Bureau Scientific Misconduct Policy
What Does Debarment Mean?
Office of Research Integrity (ORI)

 
 
Home | Contact us | Privacy policy | Terms of use | Site Map

Copyright ©1998-2013 John Stroger Hospital. All rights reserved.
All information is not a substitute for medical advice or treatment for specific medical conditions.
If you have any health-care related questions or suspect you have a health problem, you should consult your health-care provider.